Related Experiment Video
Updated: Aug 20, 2026
A Murine Closed-chest Model of Myocardial Ischemia and Reperfusion
Published on: July 17, 2012
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
Amal K Bose1, Mihaela M Mocanu, Richard D Carr
1The Hatter Institute for Cardiovascular Studies, University College London Hospital and Medical School, Grafton Way, London WC1E, UK.
Abstract:
Glucagon-like peptide 1 (GLP-1), a gut incretin hormone that stimulates insulin secretion, also activates antiapoptotic signaling pathways such as phosphoinositide 3-kinase and mitogen-activated protein kinase in pancreatic and insulinoma cells. Since these kinases have been shown to protect against myocardial injury, we hypothesized that GLP-1 could directly protect the heart against such injury via these prosurvival signaling pathways. Both isolated perfused rat heart and whole animal models of ischemia/reperfusion were used, with infarct size measured as the end point of injury. In both studies, GLP-1 added before ischemia demonstrated a significant reduction in infarction compared with the valine pyrrolidide (an inhibitor of its breakdown) or saline groups. This protection was abolished in the in vitro hearts by the GLP-1 receptor antagonist exendin (9-39), the cAMP inhibitor Rp-cAMP, the PI3kinase inhibitor LY294002, and the p42/44 mitogen-activated protein kinase inhibitor UO126. Western blot analysis demonstrated the phosphorylation of the proapoptotic peptide BAD in the GLP-1-treated groups. We show for the first time that GLP-1 protects against myocardial infarction in the isolated and intact rat heart. This protection appears to involve activating multiple prosurvival kinases. This finding may represent a new therapeutic potential for this class of drug currently undergoing clinical trials in the treatment of type 2 diabetes.
Insights
Glucagon-like peptide 1 (GLP-1) protects the heart from injury by activating prosurvival pathways. This finding suggests GLP-1 may offer new therapeutic potential for heart conditions.
Area of Science:
- Cardiology
- Endocrinology
- Molecular Biology
Background:
- Glucagon-like peptide 1 (GLP-1) is an incretin hormone that stimulates insulin secretion.
- GLP-1 activates antiapoptotic signaling pathways, including phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK).
- These kinases are known to protect against myocardial injury.
Purpose of the Study:
- To investigate the direct cardioprotective effects of GLP-1 against ischemia/reperfusion injury.
- To determine if GLP-1 utilizes PI3K and MAPK signaling pathways for its protective effects in the heart.
Main Methods:
- Experiments were conducted using isolated perfused rat hearts and whole animal models of ischemia/reperfusion.
- Infarct size was measured to quantify myocardial injury.
- Specific inhibitors and antagonists (exendin (9-39), Rp-cAMP, LY294002, UO126) were used to block GLP-1 signaling pathways.
- Western blot analysis was performed to assess protein phosphorylation.
Main Results:
- GLP-1 significantly reduced infarct size in both isolated perfused rat hearts and whole animal models compared to controls.
- The cardioprotective effects of GLP-1 were abolished by GLP-1 receptor antagonist and inhibitors of cAMP, PI3K, and MAPK pathways.
- Western blot analysis showed increased phosphorylation of the proapoptotic peptide BAD in GLP-1 treated groups.
Conclusions:
- GLP-1 demonstrates direct cardioprotective effects against myocardial infarction in rat models.
- These protective effects are mediated through the activation of prosurvival signaling kinases, including PI3K and MAPK.
- GLP-1 represents a potential therapeutic agent for myocardial infarction and related cardiovascular conditions.
